HAVCR2 and non-small cell lung carcinoma: In this context, cobolimab, a mAb of the IgG4 subclass targeting TIM-3, demonstrated a favorable safety profile both as monotherapy and in combination with dostarlimab (an anti-PD-1 agent), although its initial antitumor activity in NSCLC patients was limited [107].